What is InteRNA Technologies?
InteRNA Technologies, based in Nijmegen, Netherlands, is a clinical-stage biotechnology firm dedicated to the development of novel microRNA (miRNA) therapeutics. The company's focus lies in targeting critical pathways involved in the initiation and progression of various human diseases, with a particular emphasis on oncology. By leveraging proprietary miRNA technology, InteRNA aims to create innovative treatments for challenging medical conditions, positioning itself as a key player in the advanced therapeutics market.
How much funding has InteRNA Technologies raised?
InteRNA Technologies has raised a total of $32.9M across 2 funding rounds:
Series A
$10.5M
Series B
$22.4M
Series A (2015): $10.5M with participation from INKEF Capital and Aglaia Biomedical Ventures B.V.
Series B (2021): $22.4M led by waterman-ventures.com, Aglaia Oncology Funds, Oost NL, and AurorA Science
Key Investors in InteRNA Technologies
INKEF Capital
INKEF Capital is a Dutch venture capital firm established in 2010, managing €500 million and specializing in long-term collaboration with innovative technology companies, with a focus on Healthcare, Technology, IT/New Media & FinTech.
Aglaia Biomedical Ventures B.V.
Aglaia Oncology Funds is a specialist investor in oncology, focusing on early-stage breakthrough inventions in cancer prevention, diagnosis, and therapy. With extensive experience since 2004, Aglaia has a strong track record in launching and maturing biotech companies dedicated to oncology.
Oost NL
Oost NL is an investment and development company focused on the economic development of the eastern Netherlands, supporting innovative businesses and fostering growth in the region.
What's next for InteRNA Technologies?
The recent major strategic investment signals a pivotal moment for InteRNA Technologies, likely enabling the company to accelerate its clinical development programs and expand its research initiatives. This capital infusion is expected to support the progression of its proprietary miRNA therapeutics through further clinical trials, potentially leading to significant advancements in cancer treatment. The company's trajectory suggests a focus on scaling operations and advancing its pipeline towards commercialization, attracting further strategic partnerships and investment.
See full InteRNA Technologies company page
